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1  | INTRODUCTION
Severe vasoplegia is an important complication of cardiopulmonary 
bypass (CPB) and cardiac surgery that can develop in 5%- 44% of 
cases.1-3 Patients undergoing orthotopic heart transplantation (OHT) 
are among those of highest risk for perioperative vasoplegic syndrome 
(VS), with the severity of vasoplegia greater in this group than in non-
transplant subjects.2,4,5 The perioperative loss of systemic vascular 
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Aim: The aim of this study was to assess the influence of intraoperative cytokine ad-
sorption on the perioperative vasoplegia, inflammatory response and outcome during 
orthotopic heart transplantation (OHT).
Methods: Eighty- four OHT patients were separated into the cytokine adsorption 
(CA)- treated group or controls. Vasopressor demand, inflammatory response de-
scribed by procalcitonin and C- reactive protein, and postoperative outcome were as-
sessed performing propensity score matching.
Results: In the 16 matched pairs, the median noradrenaline requirement was signifi-
cantly less in the CA- treated patients than in the controls on the first and second post-
operative days (0.14 vs 0.3 μg*kg−1*min−1, P = .039 and 0.06 vs 0.32 μg*kg−1*min−1, 
P = .047). The inflammatory responses were similar in the two groups. There was a 
trend toward shorter length of mechanical ventilation and intensive care unit (ICU) stay 
in the CA- treated group compared to the controls. No difference in adverse events was 
observed between the two groups. However, the frequency of renal replacement ther-
apy was significantly less in the CA- treated patients than in the controls (P = .031).
Conclusions: Intraoperative CA treatment was associated with reduced vasopressor 
demand and less frequent renal replacement therapy with a favorable tendency in 
length of mechanical ventilation and ICU stay. CA treatment was not linked to higher 
rates of adverse events.
K E Y W O R D S
cardiac surgery, cytosorb, heart transplantation, hemoadsorption, inflammatory response, 
procalcitonin
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resistance with concomitant hypotension and tissue hypoperfusion 
can adversely influence the length of mechanical ventilation, intensive 
care unit (ICU) stay, morbidity, and mortality after cardiac surgery as 
well as OHT.4,5 If the vasoplegia is resistant to catecholamines, the 
mortality rate can be as high as 25%.2
The exact pathomechanism of perioperative vasoplegia remains 
poorly understood.2,4 However, it is based on an exaggerated inflam-
matory response determined by the interaction between the immune 
system priming and CPB surgery, resulting in excessive release of va-
soactive mediators and endothelial injury.2,4,6 Patients with advanced 
stage chronic heart failure are known to have elevated plasma concen-
trations of pro- inflammatory cytokines and chemokines such as tumor 
necrosis factor α (TNF- α), interleukin (IL)- 6, and IL- 8 correlating with 
the progression of heart failure.7,8 CPB surgery is also proven to gen-
erate systemic inflammatory response syndrome (SIRS) through com-
plement and cytokine activation and ischemia- reperfusion injury.9,10 
Additionally, the graft tissue induced response of the host immune 
system can further aggravate these processes in OHT.4
The conventional treatment of vasoplegia consists of fluid re-
suscitation, administration of catecholamine agents, and arginine- 
vasopressin or terlipressin.2 Nevertheless, using vasoconstrictors in 
high doses, particularly in noradrenaline- refractory cases, increases 
the risk of peripheral or mesenteric ischemia, leading to a higher rate 
of postoperative morbidity and mortality.2,6 The use of intravenous 
methylene blue (MB) as an adjuvant might have the potential to con-
trol noradrenaline- refractory VS via the inhibition of nitric oxide syn-
thase and nitric oxide in the pathway of activating soluble guanylate 
cyclase, a key element in the pathomechanism of VS.2,6,11 Despite the 
significant number of clinical investigations in the field of cardiac and 
noncardiac surgeries, MB treatment remains controversial in terms of 
therapeutic effectiveness and in reducing morbidity and mortality.6,11
The extracorporeal cytokine hemoadsorption (CytoSorb™) is a 
novel nonpharmacologic technology, which can effectively remove 
mid- molecular weight pro- and anti- inflammatory cytokines up to ap-
proximately 55 kDa such as TNF- α, IL- 1β, IL- 6, and IL- 10.12-15 Recent 
animal studies have demonstrated its benefit with hemodynamic sta-
bility and outcome in a severe sepsis model.12,14 Clinical data of pa-
tients with septic shock or post- CPB SIRS have also supported the 
effectiveness of CytoSorb™ treatment, showing hemodynamic im-
provements and reduction of vasoconstrictors.16-19
The aim of this observational study was to explore whether pre- 
emptive intraoperative use of CytoSorb™ treatment could influence 
the severity of perioperative vasoplegia, postoperative inflammatory 
response, and clinical outcome in patients undergoing OHT.
2  | MATERIALS AND METHODS
2.1 | Patients
This study analyzed prospectively collected clinical data of adult or-
thotopic heart transplantations performed between January 1, 2015 
and December 1, 2016. The study was approved by the Regional and 
Institutional Committee of Science and Research Ethics, and written 
informed consent requirement was waived (No: 246/2016). Exclusion 
criteria were retransplantation and early postoperative death within 
72 hours.
2.2 | Anesthetic procedure
Anesthesia was provided using sufentanyl bolus 0.25 μg/kg intra-
venously (IV), propofol bolus 1 mg/kg IV, atracurium bolus 0.3 mg/
kg IV for induction, then a combination of sevoflurane (minimal al-
veolar concentration: 0.7- 1.2), propofol continuous IV infusion 
(3- 5 mg*kg−1*h−1), and sufentanyl boluses for maintenance of anes-
thesia including CPB period. Intraoperative monitoring of patients 
included the standards of cardiac anesthesia including arterial blood 
pressure, central venous pressure, nasopharyngeal temperature meas-
urements, which was extended with pulmonary artery (PA) pressure 
monitoring via a PA catheter and continuous transesophageal echo-
cardiography according to the institutional OHT protocol. CPB was 
provided by roller- pump (SORIN S5 Perfusion System, Sorin Group 
Deutschland GmbH, Munich, Germany) and a membrane oxygenator 
(Sorin Inspire P8, Sorin Group Italia Srl, Mirandola, Italy) maintaining 
nonpulsatile flow rate of 2.4 L*min−1*m−2. The CPB prime was com-
posed of 1200 mL Ringer- lactate, 100 mL mannitol, and 60 mL so-
dium bicarbonate 8.4%. All patients were anesthetized by consultant 
anesthetists experienced in cardiac anesthesia and OHT.
2.3 | Perioperative care
All patients received standardized intra- and postoperative care ac-
cording to the institutional protocol. Noradrenaline was used as 
the first line vasopressor, and continuous terlipressin IV infusion 
(0- 2.0 μg*kg−1*h−1) was administered as the second- line vasopres-
sor. Terlipressin infusion was indicated if noradrenaline support ex-
ceeded 0.3 μg*kg−1*min−1. The inotrope therapy consisted of the 
combination of dobutamine (3.0- 5.0 μg*kg−1*min−1) and milrinone 
(0.35 μg*kg−1*min−1). Patients with confirmed elevated pulmonary vas-
cular resistance (PVR) received inhalational nitric oxide (0- 25.0 ppm) 
during mechanical ventilation (MV) and enteral sildenafil (60 mg/day) 
as a maintenance therapy in the postoperative period. The major 
hemodynamic targets were the following: mean arterial blood pressure 
(MAP)	≥	65	mm	Hg,	 cardiac	 index	 (CI)	≥	2.0	L*min−1*m−2, PVR < 3.0 
Wood unit, and mixed venous oxygen saturation (SvO2)	≥	65%.	
Intraoperative invasive hemodynamic monitoring was extended for 
the first 48 hours routinely. Function of the cardiac allograft was 
checked with echocardiography (transthoracic or transesophageal) 
daily during the first five post- transplant days and on a weekly basis 
thereafter.
We applied differential hemostasis management using fibrin-
ogen concentrate (Haemocomplettan™, CSL Behring, Marburg, 
Germany), prothrombin- complex concentrate (Beriplex™, CSL 
Behring) and blood products based on the results of Rotational 
Thrombelastometry (ROTEM™, Tem International GmbH, Munich, 
Germany), multiple electrode aggregometry (Multiplate™, Roche 
Diagnostics International Ltd, Rotkreuz, Switzerland), and the 
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static coagulation profile of the patients. The transfusion trigger 
was adjusted to the latest recommendations related to cardiac 
surgery.20,21
The immunosuppression therapy of the heart transplant recipi-
ents consisted of mycophenolate mofetil orally 90 minutes before the 
operation (1.5 g) and daily after the heart transplantation (2.0- 3.0 g/
day); methylprednisolone 500 mg IV prior to induction of anesthesia, 
500 mg IV 30 minutes after the aortic declamp, 125 mg IV over the 
first 3 days, and then was continued as oral maintenance treatment; 
anti- thymocyte globulin IV infusion (1.5 mg/kg) for the first three 
postoperative days; tacrolimus orally (0.1- 0.2 mg*kg−1*day−1) from the 
fifth post- transplant day targeting serum concentration of 10- 15 ng/
mL. To exclude early graft rejection, patients were followed up with 
endomyocardial biopsy weekly during the first month after the heart 
transplantation.22
2.4 | Cytokine adsorption treatment
Selection of heart transplant recipients to receive intraoperative 
cytokine adsorption (CA) treatment (CytoSorb™, CytoSorbents 
Europe GmbH, Berlin, Germany) was based on expert opinion. End- 
stage heart failure patients complicated by one or more organ dys-
functions prior to heart transplantation, poor functional status with 
expectation of developing severe VS in the perioperative period 
had priority for introducing intraoperative CytoSorb™ treatment. 
CytoSorb™ was applied for a one- cycle treatment during CPB. The 
300- mL CytoSorb™ cartridge was positioned after the oxygenator 
providing near maximal blood flow through the cartridge via a speci-
fied side branch of the CPB circuit. The estimated flow rate through 
CytoSorb™ was between 400 mL/min and 500 mL/min depending 
on the individual flow rate of CPB for all treatments. Taking into ac-
count the adsorption spectrum of CytoSorb™ (5- 55 kDA fat soluble 
agents) and its possible effect on drug serum concentration,23 we 
considered methylprednisolone (molecular weight < 1 kDA, water 
soluble) as an immunosuppressive agent, which is not affected and 
mycophenolate- mofetil (MMF; molecular weight < 1 kDA, slightly 
water soluble: pKa = 8.5) as an immunosuppressive agent, which 
is partly, but not significantly affected by CytoSorb™ adsorption. 
Supplementary doses of MMF were not administered during the 
CPB period.
2.5 | Measurement of inflammatory markers
C- reactive protein (CRP) and procalcitonin (PCT) were measured from 
venous blood routinely at six time points during the perioperative pe-
riod in all patients according to the institutional OHT protocol: prior to 
heart transplantation and daily for the first 5 days postoperatively. PCT 
was quantified by electrochemiluminescence immunoassay (Elecsys 
BRAHMS PCT, Roche Diagnostics GmbH, Mannheim, Germany), and 
CRP concentration was measured by particle enhanced turbidimetric 
assay (COBAS INTEGRA C- Reactive Protein Latex, Roche Diagnostics 
GmbH). A PCT of 0.5 μg/L and CRP of 5.0 mg/L were considered as 
the upper limits of their normal ranges.
2.6 | Outcome parameters
Primary outcome was defined as hemodynamic stability and vasopres-
sor demand during the first 48 hours postoperatively and magnitude 
of postoperative inflammatory response described by the kinetics of 
PCT and CRP. Secondary outcome parameters were the following: 
volume of postoperative bleeding; rate of reoperation for bleeding/
tamponade; need for blood products in the first 24 hours, length of 
MV; rate of primary graft failure, postoperative mechanical circulatory 
support, acute kidney injury (AKI), postoperative renal replacement 
therapy (RRT), sepsis and early cardiac allograft rejection; length- of- 
ICU stay, length- of- hospital stay, and 30- day mortality.
2.7 | Statistical analysis
Continuous variables were analyzed by the Shapiro- Wilk test for nor-
mality. Descriptive statistics of data were expressed as mean ± stand-
ard deviation and median [interquartile range]. Categorical variables 
were presented as number of patients and percentage. Unpaired t 
test, Mann- Whitney U test, and χ2 test or Fisher’s exact test were used 
for the unmatched comparisons of continuous and categorical vari-
ables where appropriate. To improve the imbalance in patients’ base-
line characteristics, we performed propensity score matching (PSM) 
using 1:1 match, nearest neighbor method with a caliper width of 
0.2.24 After the univariate analyses of the parameters listed in Table 1, 
variables that showed significant differences between the two groups 
were used as covariates in the PSM apart from Seattle Heart Failure 
Score, IMPACT score and high urgent status. Angiotensin converting 
enzyme inhibitor use, hemoglobin, bilirubin, C- reactive protein, pro-
calcitonin, pretransplant hospitalization, and pretransplant inotrope 
support from the preoperative variables, and the number of packed 
red cell transfusions from the intraoperative variables were finally 
adjusted as covariates. The change in overall imbalance after PSM 
was analyzed for improvement calculating L1 value and standardized 
mean differences of all covariates.25,26 The comparative analyses of 
outcome parameters in the matched cohort of control and treated pa-
tients were performed by paired t test and Wilcoxon rank- sum test 
for continuous variables where appropriate and the McNemar test for 
categorical variables. To identify independent predictors of second-
ary outcome parameters, we used binomial logistic regression with 
step forward likelihood ratio method. Statistical significance was de-
fined at P < .05 level in all tests. Analyses were performed with IBM 
SPSS Statistics for Windows, version 20.0. (IBM Corp., Armonk, NY, 
USA) and R- statistics for Windows, version 2.12.2 (R Foundation for 
Statistical Computing, Vienna, Austria).
3  | RESULTS
Ninety- one orthotopic heart transplantations were performed be-
tween January 2015 and December 2016 at the Heart and Vascular 
Centre of Semmelweis University. Seven patients were excluded from 
the study, of which five patients reached the exclusion criteria due to 
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TABLE  1 Patient characteristics and perioperative clinical data in control and cytokine adsorption- treated groups
Control group 
 (n = 60)
CA- treated group 
 (n = 24) P
Preoperative variables
Recipient age, years 54 (45, 58) 51 (37, 58) .685a
Male gender, n 47 (78.3%) 21 (87.5%) .539b
Body mass index, kg/m2 26.6 (24.0, 29.8) 25.4 (22.8, 27.0) .081a
DM, n 10 (16.7%) 4 (16.7%) 1.0b
CRF, n 15 (25%) 10 (41.7%) .182b
Chronic RRT, n 1 2 .238b
DCM, n 59 (98.3%) 24 (100%) 1.0b
PVR, Wood units 2.7 ± 1.3 2.9 ± 1.2 .425c
ACEI, n 45 (75%) 11 (45.8%) .020b
Amiodarone, n 8 (13.3%) 4 (16.7%) .735b
Hemoglobin, g/dL 13.0 ± 2.1 11.4 ± 3.0 .024c
Hematocrit 0.38 (0.36, 0.43) 0.36 (0.33, 0.48) .580a
Creatinine, μmol/L 97.0 (83.5, 132.0) 104.0 (83.8, 120.3) .939a
Bilirubin, μmol/L 11.7 (7.5, 18.3) 20.4 (13.4, 28.7) .003a
INR 1.5 (1.1, 2.2) 1.4 (1.2, 1.9) .719a
Fibrinogen, g/L 3.7 (2.9, 4.3) 4.1 (3.0, 5.5) .169a
CRP, mg/L 4.2 (1.7, 5.8) 12.6 (3.8, 40.4) <.0001a
PCT, μg/L 0.11 (0.05, 0.12) 0.27 (0.14, 0.27) <.0001a
WBC, G/L 8.3 ± 2.2 8.9 ± 3.3 .383c
Hospitalized prior to OHT, n 12 (20%) 13 (54.2%) .003b
Inotrope support prior to OHT, n 5 (8.3%) 12 (50%) <.0001b
Mechanical ventilation, n 0 1 .4b
Pretransplant MCS, nd 5 (8.3%) 5 (20.8%) .140b
Seattle Heart Failure Score 83.5 ± 15.0 74.5 ± 16.3 .017c
IMPACT score 2 (0, 3) 7 (1, 13) .001a
Referred to High Urgent list, n 7 (11.7%) 10 (41.7%) .005b
Intraoperative variables
Redo cardiac surgery, n 7 (11.7%) 2 (8.4%) .272b
Donor age, years 40 ± 10 42 ± 13 .542c
CIT, minutes 205 (177, 225) 212 (168, 282) .362a
CPB, minutes 194 (172, 204) 203 (185, 235) .117a
PRBC transfusion, units 1 (0, 2) 3 (0, 4) .011a
FFP transfusion, units 2 (2, 3) 3 (2, 3) .153a
Platelet transfusion, units 12 (12, 16) 12 (12, 16) .618a
Data are expressed as median (interquartile range), number of patients (percent), and mean ± standard deviation.
CA, cytokine adsorption; DM, diabetes mellitus; CRF, chronic renal failure; RRT, renal replacement therapy; DCM, dilatative cardiomyopathy; PVR, pulmo-
nary vascular resistance; ACEI, angiotensin- converting enzyme inhibitor; INR, international normalized ratio; CRP, C- reactive protein; PCT, procalcitonin; 
WBC, white blood cell; OHT, orthotopic heart transplantation; MCS, mechanical circulatory support; IMPACT score, Index for Mortality Prediction After 
Cardiac Transplantation27; CIT, cold ischemic time; CPB, cardiopulmonary bypass; PRBC, packed red blood cell; FFP, fresh frozen plasma.
aMann- Whitney U test.
bχ2 test or Fisher’s exact test.
cUnpaired t test.
dMCS consists of five left ventricular assist devices (LVAD) in the control group and three LVADs and two biventricular assist devices in the CA- treated 
group.
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death within 72 hours after the heart transplantation and other two 
patients had retransplantations. The mean age of the study popula-
tion was 50 ± 10 years and 81% of them were male. Intraoperative 
CA was used in 24 cases (28.6%). The baseline characteristics and the 
perioperative clinical data of the study cohort are shown in Table 1.
Propensity score matching from the study cohort of 60 controls 
and 24 CA- treated patients gave 16 matched pairs. After the matching 
L1 decreased from 0.842 to 0.800 indicating an improvement in overall 
balance of covariates, and the absolute values of standardized mean 
differences were less than 0.25 in all baseline variables. Data of the 
matched population are summarized in Table 2.
3.1 | Primary outcome of propensity- 
matched comparison
Median noradrenaline requirements were similar in the control and 
CA- treated groups during the heart transplantation procedure (0.15 
[0.05, 0.22] μg*kg−1*min−1 vs 0.1 [0.04, 0.25] μg*kg−1*min−1, P = .96, 
TABLE  2 Propensity score- matched data of patient characteristics and perioperative clinical variables
Control group 
 (n = 16)
CA- treated group 
 (n = 16) P
Preoperative variables
Recipient age, years 50 ± 7 51 ± 14 .762a
Male gender, n 10 (62.5%) 13 (81.3%) .433b
Body mass index, kg/m2 27.1 ± 4.0 25.3 ± 3.0 .165a
DM, n 2 (12.5%) 3 (18.8%) 1.0b
CRF, n 4 (25%) 5 (31.2%) 1.0b
PVR, Wood units 2.6 ± 1.1 2.6 ± 1.0 .875a
ACEI, n 10 (62.5%) 7 (43.8%) .479b
Amiodarone, n 3 (18.8%) 3 (18.8%) 1.0b
Hemoglobin, g/dL 13.2 ± 1.9 12.7 ± 2.8 .525a
Hematocrit 0.42 (0.36, 0.48) 0.40 (0.35, 0.48) .635c
Creatinine, μmol/L 114.4 ± 44.5 105.9 ± 29.9 .549a
Bilirubin, μmol/L 17.6 ± 10.3 20.8 ± 9.0 .346a
INR 1.8 ± 0.7 1.6 ± 0.5 .413a
Fibrinogen, g/L 4.1 ± 0.6 4.1 ± 1.2 .921a
CRP, mg/L 8.8 ± 5.6 14.7 ± 29.3 .436a
PCT, μg/L 0.2 ± 0.25 0.2 ± 0.09 .953a
WBC, G/L 8.0 ± 1.6 7.9 ± 2.4 .849a
Hospitalized prior to OHT, n 5 (31.2%) 5 (31.2%) 1.0b
Inotrope support prior to OHT, n 3 (18.8%) 5 (31.2%) .685b
Pretransplant MCS, nd 2 (12.5%) 1 (6.3%) 1.0b
Intraoperative variables
Redo cardiac surgery, n 1 (6.3%) 0 .286b
Donor age, years 39 ± 11 42 ± 12 .385a
CIT, minutes 227 ± 42 206 ± 51 .220a
CPB, minutes 211 ± 53 203 ± 32 .640a
PRBC transfusion, units 1 (0, 2) 2 (0, 4) .381c
FFP transfusion, units 2 (2, 3) 3 (2, 3) .752c
Platelet transfusion, units 15 (12, 16) 12 (12, 16) .642c
Data are presented as mean ± standard deviation, number of patients (percent), and median (interquartile range).
The etiology of end- stage heart failure was dilatative cardiomyopathy in all cases of matched cohort.
CA, cytokine adsorption; DM, diabetes mellitus; CRF, chronic renal failure; PVR, pulmonary vascular resistance; ACEI, angiotensin- converting enzyme in-
hibitor; INR, international normalized ratio; CRP, C- reactive protein; PCT, procalcitonin; WBC, white blood cell; OHT, orthotopic heart transplantation; 
MCS, mechanical circulatory support; CIT, cold ischemic time; CPB, cardiopulmonary bypass; PRBC, packed red blood cell; FFP, fresh frozen plasma.
aPaired t test.
bMcNemar test.
cWilcoxon rank- sum test.
dMCS consists of two left ventricular assist devices in the control group and one biventricular assist device in the CA- treated group.
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respectively). However, it was significantly higher in the control group 
compared to the CA- treated group during the first 24 hours’ post- 
transplantation (0.3 [0.12, 0.35] μg*kg−1*min−1 vs 0.14 [0.05, 0.18] 
μg*kg−1*min−1, P = .039, respectively) and on the second postoperative 
day (0.32 [0.07, 0.38] μg*kg−1*min−1 vs 0.06 [0.01, 0.2] μg*kg−1*min−1, 
P = .047, respectively) (Figure 1). The median terlipressin dose ad-
ministered intraoperatively (control group: 0 [0, 0.24] μg*kg−1*h−1 vs 
CA- treated group: 0 [0, 0.3] μg*kg−1*h−1, P = .94) and on the first post- 
transplant day (control group: 0.7 [0.05, 0.8] μg*kg−1*h−1 vs CA- treated 
group: 0 [0, 0.6] μg*kg−1*h−1, P = .16) were similar in both groups. 
Nevertheless, the terlipressin requirement was less in CA- treated 
patients than in controls on the second postoperative day with mar-
ginal significance (0 [0, 0.4] μg*kg−1*h−1 vs 0.7 [0.05, 1.2] μg*kg−1*h−1, 
P = .06, respectively). The median duration of vasopressor (controls: 5 
[2, 11] days vs CA- treated patients: 4 [2, 5] days, P = 1.0) as well as ino-
trope therapy (controls: 12 [8, 19] days vs CA- treated patients: 8 [6, 9] 
days, P = .80) was equal in both groups. Primary hemodynamic parame-
ters did not show any differences between the control and CA- treated 
groups as demonstrated by the average CI (3.4 ± 1.1 L*min−1*m−2 vs 
3.2 ± 0.9 L*min−1*m−2, P = .29, respectively), MAP (71 ± 8 mm Hg vs 
74 ± 8 mm Hg, P = .12, respectively), systemic vascular resistance index 
(SVRI; 1480 ± 499 dyne*s*cm−5*m−2 vs 1495 ± 443 dyne*s*cm−5*m−2, 
P = .89, respectively), and PVR (1.7 ± 1.0 Wood unit vs 2.0 ± 0.8 Wood 
unit, P = .42, respectively) during the first 24 hours postoperatively. 
SvO2 was in the normal range and similar in both groups (control group: 
71.2 ± 9.7% vs CA- treated group: 71.2 ± 7.7%, P = 1.0). The results of 
the hemodynamic parameters and oxygenation measured at the five 
time points in the first 24 hours can be seen in Figures 2-4. The time 
courses of lactate concentration were divergent with an overall lower 
concentration in the CA- treated group compared to the control group 
but the differences did not reach the level of significance at the meas-
urement points (Figure 4, panel B).
Procalcitonin and CRP changes showed pronounced postoperative 
inflammatory responses in the two groups. PCT peaked on the first 
postoperative day and then had a tendency to decrease over subse-
quent days (Figure 5, panel A). CRP, however, reached its highest lev-
els on the third postoperative day and declined after that (Figure 5, 
panel B). The dynamics of PCT and CRP did not vary between the 
control- and CA- treated groups. Interestingly, while the PCT peak 
showed a strong correlation with noradrenaline requirements in the 
first 24 hours in the control group (r2 = .63, P = .006), there was no 
correlation in the CA- treated group (r2 = .06, P = .51).
3.2 | Secondary outcome of propensity- 
matched comparison
There were no differences in postoperative blood loss and number 
of transfused blood products (ie, packed red blood cell, fresh frozen 
F IGURE  2 Cardiac index (A) and mean arterial pressure (B) 
during the first 24 h after orthotopic heart transplantation. Blank bar 
demonstrates controls and striped bar indicates CytoSorb™- treated 
patients. Data are presented as means. Error bars show standard 
error of the mean. Paired t test
F IGURE  1 Comparison of noradrenaline requirements in the early 
postoperative period. Blank bar demonstrates control group and 
striped bar indicates CytoSorb™- treated patients. Data are presented 
as medians. Error bars show 95% confidence interval. Wilcoxon rank- 
sum test
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plasma, and platelets) between the two groups (Table 3). Need for 
re- exploration for bleeding or tamponade was less in the CA- treated 
patients than in the control group with marginal significance (2 vs 5 
cases, P = .06, respectively). Patients in the CA- treated group expe-
rienced shorter ventilation times and less acute kidney injury but the 
differences were not statistically significant. Nevertheless, the fre-
quency of acute or acute- on- chronic renal failure requiring renal re-
placement therapy was higher in the control group than in CA- treated 
group (4 vs 2 cases, P = .031, respectively). The incidence of sepsis and 
early graft rejection did not vary in the two groups. While we did not 
find any difference in length- of- hospital stay between the two groups, 
the length- of- ICU stay was shorter in CA- treated group than in con-
trol group (10 vs 20 days, respectively) but this difference was not 
statistically significant. There were no deaths during the first month 
after transplantation in CA- treated patients compared to two cases in 
the propensity- matched control group. Details of postoperative com-
plications are summarized in Table 3. The independent predictors of 
secondary outcome parameters analyzed in the nonmatched cohort 
are shown in Table 4.
4  | DISCUSSION
This propensity score- matched cohort study aimed to explore the 
influence of intraoperative use of CytoSorb™ treatment on postop-
erative vasoplegia, inflammatory response, and clinical outcome in 
patients undergoing OHT. Our study showed that CA treatment was 
associated with less severe postoperative vasoplegia and reduced 
vasopressor demand in the first 48 hours postoperatively, despite 
similar kinetics of the inflammatory markers PCT and CRP in the 
F IGURE  3 Trends of systemic vascular resistance (A) and 
pulmonary vascular resistance (B) over the first 24 h postoperatively 
in cytokine adsorption treated patients (striped bar) and control 
group (blank bar). Data are demonstrated as means. Error bars 
correspond to standard error of the mean. Paired t test
F IGURE  4 Postoperative changes in mixed venous oxygen 
saturation (A) and lactate level (B) in the early postoperative period. 
While mixed venous oxygen saturation did not differ between 
CytoSorb™- treated patients (striped bar) and controls (blank bar), a 
substantial difference was seen in the time courses of lactate of the 
two groups. The lactate concentration normalized faster, within 24 h, 
in the CytoSorb™ treated group (red dotted line) than the control 
group (black continuous line). Data are demonstrated as means. Error 
bars correspond to standard error of the mean. Paired t test
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two groups. Patients treated with CytoSorb™ experienced shorter 
periods of postoperative MV and ICU stay. In fact, we observed less 
AKI and RRT requirement in CA- treated group than in the controls. 
Additionally, this study did not confirm higher rates of complications 
including postoperative bleeding, pericardial tamponade, sepsis, and 
early graft rejection in the CA- treated group.
Patients with end- stage heart failure undergoing OHT are at a 
remarkably higher risk for developing severe vasoplegia compared to 
nontransplant cardiac surgery patients.4,5,28 One of the main contrib-
uting factors of this difference is the post- CPB inflammatory response. 
This is more pronounced in OHT than in conventional cardiac surgery 
patients due to the pre- existing activation of the immune system by 
the advanced heart failure and reaction of the host immune system to 
graft tissue.4,29 The rational to introduce the pre- emptive intraopera-
tive CytoSorb™ treatment among OHT recipients was to mitigate and 
modify this aggravated post- CPB inflammatory response and hope-
fully prevent development of severe vasoplegia with excessive vaso-
pressor demand.
Case reports and a case series published recently demonstrated 
that CytoSorb™ treatment of patients with septic shock results in 
improved hemodynamics, significant decrease in vasopressor dose, 
and effective removal of pro- inflammatory cytokines after 24 hours 
of application.16,17,19,30 Träger et al confirmed the beneficial effects 
of postoperative CytoSorb™ treatment on hemodynamic stability and 
the control of elevated pro- inflammatory cytokines in cases of severe 
post- CPB SIRS complicated with AKI in a retrospective analysis of 16 
patients.18 However, Bernardi et al found no significant differences in 
pro- inflammatory cytokine levels and clinical outcome in cardiac sur-
gical patients when they used CytoSorb™ treatment intraoperatively 
in a blinded, randomized, controlled pilot study.31 They highlighted 
the length of treatment time (191 ± 56 minutes), concentration- 
dependent adsorption of cytokines, and strong inter- individual differ-
ences in cytokine levels as possible reasons for their findings.31 Our 
study demonstrated significantly less vasopressor requirements in 
the CA- treated patients than in controls in the first 48 hours post-
operatively (Figure 1) after an intraoperative mean treatment time 
of 203 ± 32 minutes. Despite the lower doses of noradrenaline and 
terlipressin administered in the CA- treated group in our study, we 
found similar parameters to those of controls for both hemodynam-
ics (Figures 2-3) and tissue oxygenation (Figure 4A). However, lactate 
concentrations were lower in the CA- treated patients than in controls 
over the first postoperative 24 hours (Figure 4B). Additionally, con-
founding factors in the pre- and intraoperative periods, known to in-
fluence postoperative vasopressor demand, were well balanced in the 
propensity score- matched cohort (for details see Table 2). These data 
suggest that a shorter period of intraoperative CytoSorb™ treatment 
(ie, <4 hours) can be clinically effective for controlling postoperative 
vasoplegia in OHT patients.
We analyzed PCT and CRP as inflammatory markers in the first 
five postoperative days to quantify post- CPB inflammatory response. 
CRP has some limitations in the evaluation of post- CPB inflammatory 
response, especially in the early postoperative phase. CRP increases 
after cardiac surgery regardless of the magnitude of SIRS or surgical 
trauma.32,33 PCT is a widely used diagnostic and follow- up marker of 
infective or noninfective SIRS.32,34-36 Pro- inflammatory cytokines con-
tribute to early PCT induction after surgery resulting in a peak concen-
tration within 24 hours.32,34 The peak level of PCT correlates well with 
the extent of surgical trauma, duration of aortic cross- clamp and CPB, 
and its dynamics can be a prognostic indicator of complications after 
cardiac surgery or OHT.32,34,35 In this study, we did not see differences 
in peak levels and kinetics of CRP and PCT between the CA- treated 
and control groups representing similar post- CPB inflammatory re-
sponses. However, we found a strong correlation between the PCT 
peak and the noradrenaline requirement measured on the first post-
operative day in the control group, which was not observed in the 
CA- treated patients. This interesting result is indicative of a possible 
influence of CytoSorb™ treatment on vasoactive mediators associated 
with CPB and OHT.
F IGURE  5 Comparison of postoperative inflammatory responses 
demonstrated by dynamics of procalcitonin (A) and C- reactive protein 
(B). Black continuous line demonstrates control group and red dotted 
line indicates CytoSorb™ treated group. Data are presented as 
medians. Error bars correspond to 95% confidence interval. Wilcoxon 
rank- sum test
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Peng and co- workers confirmed intense cytokine removal, better 
hemodynamics, and short- term survival after 3 hours of hemoad-
sorption treatment compared to sham therapy in an animal model of 
sepsis.14 Kogelmann et al reported lower mortality than predicted by 
the APACHE II score associated with early CytoSorb™ treatment in 
patients with septic shock.19 Interestingly, these favorable effects of 
hemoadsorption on outcome were not completely reproducible in the 
cardiac surgery setting by recent investigations.18,31 In our study, clin-
ical outcome showed a positive tendency in the CA- treated patients 
compared to controls especially in length of MV, ICU stay, frequency 
of RRT, and mortality although the observed differences in these pa-
rameters did reach the level of statistical significance, due, in part, 
to the small sample size. Furthermore, the complication profile of 
CA- treated patients was similar but definitely not inferior to controls 
in terms of postoperative bleeding, sepsis, and early graft rejection. 
These positive results can be linked at least in part to significantly 
less vasopressor demand in the early postoperative period associated 
with intraoperative CytoSorb™ treatment.
4.1 | Limitations
Our investigation does have limitations. This observational study was 
carried out in a single center which influenced the sample size for the 
study period. Patient selection for the use of intraoperative cytokine 
adsorption was based on the arbitrary criteria of clinical experts. This is 
due to the scarcity of published data in literature related to CytoSorb™ 
TABLE  3 Comparison of clinical outcome parameters in propensity score matched data
Control group  
(n = 16)
CA- treated group  
(n = 16) P
Postoperative bleeding, mL 750 (500, 1390) 685 (560, 1290) .93a
RO for bleeding/tamponade, n 5 (31.2%) 2 (12.5%) .06b
Transfusion in first 24 h
PRBC, units 2 (0, 10) 2 (1, 4) .91a
FFP, units 0 (0, 5) 1 (0, 2) .68a
Platelet, units 0 (0, 16) 0 (0, 12) .95a
Mechanical ventilation time, hours 129 (19, 386) 24 (17, 64) .29a
Mechanical ventilation >72 h, n 5 (31.2%) 3 (18.8%) .10b
PGF, n 4 (25%) 2 (12.5%) .03b
Postoperative MCS, n 4 (25%) 2 (12.5%) .03b
AKI, n 6 (37.5%) 2 (12.5%) .12b
Postoperative RRT, n 4 (25%) 2 (12.5%) .03b
Sepsis, n 5 (31.2%) 4 (25%) .14b
Early graft rejection, nc 4 (25%) 5 (31.2%) .12b
Length- of- ICU stay, days 20 (7, 45) 10 (9, 29) .89a
Length- of- hospital stay, days 30 (20, 52) 34 (26, 58) .35a
30- day mortality, n 2 (12.5%) 0 .001b
Data are presented as median (interquartile range), number of patients (percent).
CA, cytokine adsorption; RO, reoperation; PRBC, packed red blood cell; FFP, fresh frozen plasma; PGF, primary graft failure; MCS, mechanical circulatory 
support; AKI, acute kidney injury; RRT, renal replacement therapy; ICU, intensive care unit.
aWilcoxon rank- sum test.
bMcNemar test.
cEarly graft rejection was defined by the first surveillance endomyocardial biopsy (EMB) performed on the seventh post- transplant day. EMB grade 
(International	Society	for	Heart	and	Lung	Transplantation)	≥1A	was	considered	as	a	positive	result	for	early	graft	rejection.	Based	on	the	first	12	months	
follow- up data, the frequency of the cardiac allograft vasculopathy was four cases in the CA- treated group vs 0 cases in the control group, P < .0001.
TABLE  4  Independent predictors of secondary outcome 
parameters
OR 95% CI P
Postoperative bleeding:
Postoperative MCS support 4.7 1.2- 18.9 .031
Mechanical ventilation >72 h:
AKI 6.7 1.9- 23.8 .003
Intraoperative PRBC 
transfusion >4 units
11.6 2.0- 67.7 .007
Acute kidney injury:
Postoperative MCS support 5.6 1.5- 20.8 .010
Sepsis:
Hospitalization prior to OHT 3.3 1.2- 9.2 .024
Binomial logistic regression, step forward likelihood ratio.
Logistic regression did not identify independent predictors of primary graft 
failure and early graft rejection.
OR, odds ratio; CI, confidence interval; MCS, mechanical circulatory sup-
port; AKI, acute kidney injury; PRBC, packed red blood cell; OHT, orthot-
opic heart transplantation.
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treatment, particularly in field of cardiac surgery or OHT due the nov-
elty of this technology. This study completely adhered to the institu-
tional protocol for OHT; therefore, the postoperative inflammatory 
response was described only by changes in PCT and CRP, and no other 
pro- inflammatory cytokines for more specific information. These limi-
tations somewhat restrict the interpretation of our results.
5  | CONCLUSIONS
To the best of our knowledge, this is the first observational study 
presenting the use of intraoperative CytoSorb™ treatment during 
OHT. In this study, CytoSorb™ treatment was associated with sig-
nificantly reduced vasopressor requirements and less frequent RRT 
in the early postoperative period. The favorable trends in length of 
MV, ICU stay, and rate of AKI observed in the CA- treated patients 
suggest that intraoperative CytoSorb™ treatment might have benefit 
for reducing postoperative complications and improving outcome in 
the heart transplantation setting via more stable hemodynamics and 
reduced vasopressor demand. This study confirms that intraoperative 
cytokine adsorption is not linked to a higher rate of postoperative 
adverse events such as bleeding, sepsis, or early cardiac allograft 
rejection.
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